Literature DB >> 28612022

Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease.

Raja Atreya1, Markus F Neurath1.   

Abstract

The induction and subsequent maintenance of mucosal healing has emerged as one of the central therapeutic goals in the management of patients with inflammatory bowel disease (IBD) (Crohn's disease and ulcerative colitis). Current and novel treatment options are assessed regarding their therapeutic efficacy on the basis of their ability to induce mucosal healing. However, there is still substantial debate about the precise definition of mucosal healing. Here, we will give an overview regarding the definitions of mucosal healing as well as its probable effects on long-term disease behavior and finally focus on current and potential therapeutic targets to achieve this therapeutic goal in IBD patients.

Entities:  

Keywords:  Biologicals; Inflammatory bowel diseases; Mucosal healing; Oligonucleotides; Small molecules

Year:  2017        PMID: 28612022      PMCID: PMC5465787          DOI: 10.1159/000458006

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  43 in total

1.  Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.

Authors:  Haruhiko Ogata; Jun Kato; Fumihito Hirai; Nobuyuki Hida; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Koyanagi; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2011-09-01       Impact factor: 5.325

Review 2.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

3.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

4.  Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.

Authors:  Raja Atreya; Michael Zimmer; Brigitte Bartsch; Maximilian J Waldner; Imke Atreya; Helmut Neumann; Kai Hildner; Arthur Hoffman; Ralf Kiesslich; Andreas D Rink; Tilman T Rau; Stefan Rose-John; Hermann Kessler; Jan Schmidt; Markus F Neurath
Journal:  Gastroenterology       Date:  2011-08-27       Impact factor: 22.682

5.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 7.  The fundamental basis of inflammatory bowel disease.

Authors:  Warren Strober; Ivan Fuss; Peter Mannon
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

8.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

Review 9.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

10.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

View more
  13 in total

Review 1.  Biomedical potential of mammalian spectraplakin proteins: Progress and prospect.

Authors:  Sarah A King; Han Liu; Xiaoyang Wu
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-09

Review 2.  Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome.

Authors:  Larissa S Celiberto; Franziska A Graef; Genelle R Healey; Else S Bosman; Kevan Jacobson; Laura M Sly; Bruce A Vallance
Journal:  Immunology       Date:  2018-05-16       Impact factor: 7.397

Review 3.  Gut homeostasis, injury, and healing: New therapeutic targets.

Authors:  Sema Oncel; Marc D Basson
Journal:  World J Gastroenterol       Date:  2022-05-07       Impact factor: 5.374

Review 4.  Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?

Authors:  Eduardo J Villablanca; Katja Selin; Charlotte R H Hedin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-04-19       Impact factor: 73.082

5.  Improving the quality of care for inflammatory bowel disease.

Authors:  Byong Duk Ye; Simon Travis
Journal:  Intest Res       Date:  2018-11-20

6.  Dipotassium Glycyrrhizate Improves Intestinal Mucosal Healing by Modulating Extracellular Matrix Remodeling Genes and Restoring Epithelial Barrier Functions.

Authors:  Laura Stronati; Francesca Palone; Anna Negroni; Eleonora Colantoni; Anna Barbara Mancuso; Salvatore Cucchiara; Vincenzo Cesi; Sara Isoldi; Roberta Vitali
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

7.  Mucosal gene expression changes induced by anti-TNF treatment in inflammatory bowel disease patients.

Authors:  Elena Milanesi; Maria Dobre; Teodora E Manuc; Gabriel Becheanu; Cristian G Tieranu; Elena M Ionescu; Mircea Manuc
Journal:  Drug Dev Res       Date:  2019-07-19       Impact factor: 4.360

8.  Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review.

Authors:  Wan-Ting Cao; Rong Huang; Ke-Fang Jiang; Xue-Hui Qiao; Jing-Jing Wang; Yi-Hong Fan; Yi Xu
Journal:  World J Gastroenterol       Date:  2021-03-07       Impact factor: 5.742

Review 9.  Clinical importance of IL-22 cascade in IBD.

Authors:  Atsushi Mizoguchi; Arisa Yano; Hidetomo Himuro; Yui Ezaki; Takayuki Sadanaga; Emiko Mizoguchi
Journal:  J Gastroenterol       Date:  2017-10-26       Impact factor: 7.527

10.  Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study.

Authors:  Lorenzo Bertani; Corrado Blandizzi; Maria Gloria Mumolo; Linda Ceccarelli; Eleonora Albano; Gherardo Tapete; Giovanni Baiano Svizzero; Federico Zanzi; Francesca Coppini; Nicola de Bortoli; Massimo Bellini; Riccardo Morganti; Santino Marchi; Francesco Costa
Journal:  Clin Transl Gastroenterol       Date:  2020-05       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.